Haplotype (n = 302) | Age (years) | OR (95% CI)a | p b | |
> 40 | ≤40 | |||
rs1801133-rs1801131 | ||||
 C-A | 49.8% c | 49.4% | 1 | – |
 T-A | 23.9% | 26.5% | 1.08 (0.61–1.93) | 0.78 |
 C-C | 21.2% | 8.7% | 0.44 (0.16–1.16) | 0.1 |
 T-C | 5.1% | 15.4% | 3.52 (1.23–10.06) | 0.02 |
rs1799793-rs13181 | ||||
 G-A | 51.3% | 48.1% | 1 | – |
 A-A | 18.7% | 20.7% | 1.23 (0.65–2.35) | 0.53 |
 G-C | 15.5% | 18.9% | 1.33 (0.68–2.61) | 0.41 |
 A-C | 14.5% | 12.3% | 0.91 (0.47–1.76) | 0.79 |
Haplotype | Family history of breast cancer | Â | Â | |
(n = 302) | Sporadic | Familial |  |  |
rs1801133-rs1801131 | ||||
 C-A | 53.5% | 46.6% | 1 | – |
 T-A | 17.9% | 31.1% | 1.76 (0.97–3.18) | 0.063 |
 C-C | 24.5% | 7.4% | 0.36 (0.14–0.95) | 0.042 |
 T-C | 4.1% | 14.9% | 4.96 (1.50–16.42) | 0.0097 |
rs1799793-rs13181 | ||||
 G-A | 51.1% | 48.7% | 1 | – |
 A-A | 19.1% | 20.2% | 1.05 (0.56–1.98) | 0.88 |
 G-C | 18.4% | 15.5% | 0.87 (0.44–1.68) | 0.67 |
 A-C | 11.4% | 15.6% | 1.32 (0.70–2.47) | 0.39 |
Haplotype | ER and PR status | Â | Â | |
(n = 286) | ER positive | ER negative |  |  |
rs1799793-rs13181 | ||||
 G-A | 46.7% | 57.6% | 1 | – |
 A-A | 19.6% | 17.4% | 0.83 (0.38–1.81) | 0.65 |
 G-C | 15.9% | 20.2% | 1.11 (0.54–2.30) | 0.78 |
 A-C | 17.8% | 4.8% | 0.28 (0.09–0.88) | 0.03 |
rs1799793-rs13181 | PR positive | PR negative | Â | Â |
 G-A | 48.7% | 48.3% | 1 | – |
 A-A | 19.3% | 20.5% | 1.41 (0.67–2.98) | 0.36 |
 G-C | 13.1% | 25.7% | 2.34 (1.1–4.96) | 0.02 |
 A-C | 18.9% | 5.6% | 0.33 (0.12–0.92) | 0.03 |
Haplotype | Tumor size | Â | Â | |
(n = 72) | T1 | T4 |  |  |
rs1799793-rs13181 | ||||
 G-A | 55.5% | 41.7% | 1 | – |
 A-A | 17.4% | 29.2% | 2.10 (0.59–7.46) | 0.26 |
 G-C | 11.2% | 29.1% | 23.30 (2.03–267.69) | 0.017 |
 A-C | 15.9% | 0% | NA | 1 |